

ASX RELEASE

17th December 2019

Shareholder Update / 2019 Review

Amplia Therapeutics Limited (“ATX”) is pleased to provide shareholders with an end-of-year review of development activity, as well as an overview of key corporate objectives in 2020.

This year was a productive year for ATX with excellent progress of the development of Amplia’s lead Focal Adhesion Kinase (FAK) inhibitor, AMP945. During the year the company devised a method for kilo-scale manufacturing of AMP945 and filed important new intellectual property for an optimised oral drug formulation. In addition, the company completed several key preclinical studies to support translation into the clinic. A presentation summarising our achievements in 2019 is available at the [ATX website](#).

2020 corporate objectives include:

1. Initiation of the first clinical trials of AMP945 in both cancer patients and healthy volunteers (to support the fibrosis indications) – under CTN studies in Australia.
2. Further pre-clinical development to support the clinical evaluation of the AMP886 asset for use in oncology.
3. Pharma business development activity around ATX’s core assets, including several collaboration opportunities that are likely to materialise based on planned data acquisition.
4. Completion of IND-enabling studies that will support a rapid Phase II oncology combination therapy pathway for AMP945 in the US, subject to feedback from the FDA.

ATX’s Board and Management would like to express their appreciation to shareholders for their support of the company during 2019. In 2020 we look forward to advancing ATX’s lead program into the clinic, with the associated value inflection of becoming a clinical-stage biotechnology company¹.

Authorised by the Board. For further details contact:

Dr John Lambert
Chief Executive Officer
john@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics is a biopharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) small molecule inhibitors to address serious unmet

¹ Subject to requisite regulatory and ethics approvals.

medical needs in cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a development focus in pancreatic and ovarian cancer. FAK may also play a significant biological role in the progression of chronic fibrotic diseases, such as hepatic fibrosis and idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics is listed on the Australian Securities Exchange (ASX.ATX). For information about Amplia Therapeutics and its pipeline, please visit our website at ampliatx.com.

Shareholder Update

December 2019

Amplia Therapeutics Limited
ASX: ATX



Notice




The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“ATX”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to ATX, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of ATX’s acquired product pipeline. Actual results from clinical trials may vary from those shown.


Investment Highlights

- ATX's technology addresses a multi-\$Bn market opportunity:
 - ✓ Unmet clinical need in pancreatic and ovarian cancer
 - ✓ Impact in chronic fibrotic diseases: hepatic, pulmonary
- Experienced team with a stellar record in drug development and partnering
- 2019 was pivotal in terms of advancement toward the clinic and commercial execution




Multiple 'shots on goal' for ATX's pipeline

Cancer



Fibrosis



2019: Accomplishments

ATX has established the foundation for clinical development of its FAK assets

- ✓ Modest capital raise
- ✓ GMP¹ drug manufacture at **kilogram scale**
- ✓ Safety studies in two species to support clinical translation with **clear evidence of safety**
- ✓ Clinical trial design and establishment of **relationships with Key Opinion Leaders** (KOLs)
- ✓ Efficacy studies that demonstrate ATX's molecules are **highly differentiated / competitive**
- ✓ Further meaningful protection of our intellectual property through new IP capture and extension of **patent life out to late 2032**

¹ Good Manufacturing Practice.



Toward Clinical Studies

During 2019, ATX established collaborations with clinical KOLs in Australia and Internationally

- ✓ Multiple opportunities for innovative and cost-effective clinical trials of ATX's FAK inhibitors in both cancer patients and healthy volunteers to support a range of indications
- ✓ Rapid pathway to Phase II studies internationally in key cancer indications (pancreatic and ovarian cancer)



Drug Manufacturing and Intellectual Property

Amplia has filed new international patents to protect the optimal formulation of the lead candidate (AMP945)

- ✓ The optimised form of AMP945 has now been manufactured at kg scale by a reputable contract manufacturer
- ✓ Suitable for clinical use, plenty of material to support planned clinical studies, oral use (once daily)
- ✓ Has been on a stability program for 9 months (bulk drug stability)
- ✓ Has remained stable, retained requisite pharmaceutical potency



Safety Profiling of AMP945


AMP945 has been tested in preclinical safety studies in two species

- These studies provide a valuable preliminary view of AMP945's toxicology
 - ✓ Enable confident dose selection
- The aims of these studies were met
 - ✓ No unexpected findings were made in preliminary studies
 - ✓ Dose ranges have been selected for further toxicology studies to support both healthy volunteer studies and US IND requirements



ATX's Lead Program (AMP945) is Differentiated

- Non-selective kinase inhibitors may exhibit more clinical side-effects / toxicity
 - ✓ We already know that AMP945 is a highly selective inhibitor of FAK
 - ✓ AMP945 has a very 'clean' kinome profile
- We have now run a study to directly compare AMP945's selectivity to that of our closest competitor, defactinib (Verastem)
 - ✓ As expected, AMP945 was shown to be much more selective for FAK than defactinib
 - ✓ Fewer off-target effects
 - ✓ Likely to be better tolerated in patients than defactinib



AMP945 is a more selective inhibitor than defactinib

2020 Corporate Objectives

- Initiation of the first clinical trials of AMP945
- Further pre-clinical development to support the clinical evaluation of AMP886
- Pharma business development activity around ATX's core assets
- Completion of IND-enabling studies that, subject to regulatory approvals, will support a rapid Phase II oncology combination therapy





For further information please contact

John Lambert PhD
Chief Executive Officer

john@ampliatx.com
www.ampliatx.com